Company: ADPT
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0000950170-25-103120
Chunk: 5

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 2
Chunk 5
---
 and $93.7 million for the six months ended June 30, 2025 and 2024, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering and follow-on offering, and, to a lesser extent, revenue and proceeds from the revenue interest purchase agreement we entered into in September 2022 (the “Purchase Agreement”). As of June 30, 2025 and December 31, 2024, we had cash, cash equivalents and marketable securities of $222.0 million and $256.0 million, respectively.